CKDB-501B

CKDB-501B is an investigational drug developed by CKD Bio, currently in clinical trials. It is being evaluated in a randomized, double-blind, active-controlled Phase I trial for safety and efficacy in subjects with moderate-to-severe glabellar lines[1]. While detailed mechanistic information specific to CKDB-501B is not available from the provided sources, it appears closely related to other agents in the "CKDB-501" series (such as CKDB-501A), which are described as neuromodulators based on botulinum toxin serotype A (BoNT/A). These drugs act by inhibiting synaptic vesicle fusion proteins such as SNAP25, thereby blocking acetylcholine release at neuromuscular junctions and causing temporary muscle paralysis. The primary indication under investigation for this class of drugs is cosmetic treatment of glabellar lines; however, similar agents are also being explored for neuropsychiatric disorders. The developer and likely manufacturer is CKD Bio.